Leonard Calabrese LCalabreseDO
7 years ago
Looking forward to giving plenary talk at #ACR2019 at 11AM Sunday on practical aspects of vaccines(flu/pneumo/VZV) for autoimmune pts @paijournal @IDSA @RheumNow @HealioRheum @AdamJBrownMD @ELittlejohnDO @RulaHajjAliMD https://t.co/UIYBIBDeSe
Dr. John Cush RheumNow
7 years ago
Get the FREE RheumaKnowledgy Card - a pocket guide/aid to the diagnosis, testing and Rx of Rheumatologic, autoimmune and other MSK complaints. https://t.co/oMa3qzh7xt
Dr. John Cush RheumNow
7 years ago
NEJM: Synovial Chondromatosis. A 46-year-old woman with rheumatoid arthritis presented with pain and swelling in both knees. Radiographic findings were consistent with synovial chondromatosis. https://t.co/9jMzE0fuNE
Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).
A retrospective study of interstitial lung disease (ILD) patients from the Columbia University Irving Medical Center (2009 to 2017) looked for those who did or did not meet IPAF criteria.
Dr. John Cush RheumNow
7 years ago
N. Zealand study shows their cost of knee OA was $200 million in 2013; and without any changes in the standards of care, this isprojected to increase to $370 million by 2038. (includes an additional 4,000 TKRs per year by 2038). https://t.co/B1awh1ky1B
Dr. John Cush RheumNow
7 years ago
Claims study of RA, PsA, AS/SpA patients on TNF inhibitors shows a comparison of 31,527 MTX vs 34,651 TNFi initiators. MTX was D/C sooner in PsA & AS [aHR 1.10, 1.23) vs RA pts. Concomitant MTX reduced risk of TNFi D/C in all [aHR 0.85, 0.81, 0.79] https://t.co/0l2J2FDsUm
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
Dr. John Cush RheumNow
7 years ago
Might Vioxx make a backdoor comeback? 2017 Vioxx went off patent, now a small pharma has applied to the FDA for orphan drug approval of rofecoxib (& etoricoxib) to treat hemophiliac arthropathy (large unmet need). Say it aint so! https://t.co/kENHHhcyIT https://t.co/QpDNiaCZyz
Dr. John Cush RheumNow
7 years ago
Choi and colleagues have shown that allopurinol-associated severe cutaneous adverse reactions are higher with Heart (RR 1.44) and Renal (11 fold) disease. Initating low-dosage allopurinol may substantially mitigate this risk. https://t.co/gyj7Xn3uhx
Since moving to South Florida (also popularly known as "God's Waiting Room" by the locals). I've learned a lot more about Lipstick Rheumatology. This moniker was made famous by my friend and colleague, Dr. Kathryn Dao, who first wrote about the nuances of being a female with rheumatic disease. This blog focuses on three popular products recommended by my female patients that serve as life improving hacks.
The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.
Overall they have promoted 13 recommendations (7 primary and 6 secondary) strongly supported medical evidence.
Highlights include recommendations for:
JAMA Internal Medicine has an analysis of the growing trend of more women enrolling in medical schools in the last few decades, such that more than half of US Med school matriculants in 2017 were women. Also in 2017, 42% of residents in internal medicine were women. The reported analysis looked at internal medicine subspecialty choices by women and men between 1991 to 2016.
The Annals of Rheumatic Disease reports a psoriatic arthritis study where in ixekizumab was non-inferior to adalimumab for achievement of ACR50 responses but was superior to adalimumab for achievement of PASI100 by week 24.
Dr. John Cush RheumNow
7 years ago
MotherToBaby Pregnancy Study in 528 RA pts has shown oral steroid use yields a dose dependent risk of pre-term birth. PTB was increased high dose (RR: 4.77) and medium dose (aRR: 1.81) OCS in the 1st 139 gestational days; DMARDs/biologics were not https://t.co/cuggovK8eL

